Nakatani D, et al. April 2019. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management. Respiratory is one of AstraZeneca’s three main therapy areas. Please refer to your approved national product label (SmPC) for current product information. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. We strive to prevent heart disease onset, as well as treat and regenerate the heart to help protect millions of people living with heart failure. AstraZeneca has sales in 67 countries in scope. … AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. Sacco et al. Up to one in five people who have been event-free for a year may experience another heart attack within three years of the first.10 Working together with healthcare professionals, we help raise awareness of the importance of secondary prevention among heart attack survivors. our approach towards holistic care for CVRM patients, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.usrds.org/2018/view/v2_08.aspx, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack/lifestyle-changes-for-heart-attack-prevention, https://www.nhs.uk/conditions/heart-attack/prevention/, http://www.healthtalk.org/peoples-experiences/heart-disease/heart-attack/coping-emotions-after-heart-attack, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack, http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf, https://dgk.org/pressemitteilungen/2019-jahrestagung/2019-jt-statements/2019-jt-statements-tag2/neues-versorgungsforschungsprojekt-gullive-r-zur-langzeitversorgung-von-herzinfarkt-patienten-in-deutschland/, Manage other cardiovascular, renal and metabolic diseases and associated risk factors. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH). [online] Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ [Accessed 31 Jul. Our ambition is to eliminate the remaining cardiovascular (CV) risk of patients with CV disease and stopping disease progression, therefore preventing CV events from occurring and protecting the lives of millions of patients. 7. June 2019. We aim to raise awareness of common comorbidities and inspire healthcare professionals and patients alike to get involved in our holistic approach towards disease management. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Up to 94% of people with type-2 diabetes in the US have at least one additional CVRM condition.7 We work to provide solutions for these complications that might become life-threatening, to change the lives of type-2 diabetes patients by reducing risk factors through early prevention. Entering a new era in vascular and cardiac regeneration research As we move novel therapeutic modalities from the laboratory into clinical trials, we are focusing on the repair and regeneration of tissues with the potential to treat life threatening cardiovascular diseases such as heart failure. Available from URL: National Health Service. If you are in the US and would like additional information regarding AstraZeneca drugs, please contact the Information Center at AstraZeneca at 1-877-893-1510 1-877-893-1510. Cardiovascular AstraZeneca has been driving cardiovascular innovation for more than 100 years. Important notice for users AstraZeneca provides this link as a service to website visitors. 2015. United States Renal Data System. 4,5 Atherosclerotic plaque, a build-up of deposits of fatty material, cholesterol, cellular waste products and other substances, accumulate in the coronary arteries, obstructing the blood flow to the heart muscle. Wang H et al. Our focus is to transform the lives of the millions of patients living with metabolic diseases. AstraZeneca plc. AstraZeneca has a total of 79 R&D projects featuring a small-sized priority R&D pipeline compared to its peers: 4 projects. Our culture at AstraZeneca. We are exploring treatment options to reduce cardiovascular problems and death in high-risk patients, beyond acute coronary syndrome. ... Area under investigation:cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, … 2015;36(19):1163–70. You are about to access AstraZeneca historic archive material. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Cardiovascular disease. AstraZeneca's boss Pascal Soriot, said: 'The consistent achievements in the pipeline, the accelerating performance of our business and the progress … 2017;60(2):259-66. AstraZeneca are also developing testicular cancer drug Lynparza which has had positive findings from trials. Knuuti J et al. AstraZeneca is not responsible for the privacy policy of any third party websites. 2013;77(2):439-46. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Our 40-year heritage in respiratory medicines is just the beginning of our story. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed.4,5 Atherosclerotic plaque, a build-up of deposits of fatty material, cholesterol, cellular waste products and other substances, accumulate in the coronary arteries, obstructing the blood flow to the heart muscle.5 The plaque can cause a partial or complete blockage of blood supply to the heart muscle, which can cause a heart attack.4,5, We are seeing that patient therapy goes beyond treating one disease. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. R.L. Diabetes Obes Metab 2018; 20(8):2000–3. Neues Versorgungsforschungsprojekt GULLIVE-R zur Langzeitversorgung von Herzinfarkt-Patienten in Deutschland. We encourage you to read the privacy policy of every website you visit. Lifestyle Changes for Heart Attack Prevention. AstraZeneca UK aims to support local innovation and best practice that improves patient care in Respiratory, Immunology, Cardiovascular, Metabolic, Renal and Oncology therapy areas. 's AZN stock has rallied 11.9% this year so far, outperforming the industry's rise of 3.7%. AstraZeneca and Ionis have a strategic alliance focused on leveraging antisense technology to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. 2010;304(12):1350-7. Available from URL: Bloom DE, et al. The other 75 R&D projects target other diseases in scope. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas. 2015;132(10):923–31. Since 2014, there has been a 75% compliance rate among those hospitals involved. Available from URL: Roth G, et al. (Fast Track, Breakthrough Therapy Designation). Report a Side Effect uk-drugsafety@sanofi.com +44 (0) 800 0902314 (Monday - Friday) Fax: +44 (0) 800 4716122 Please note, we cannot provide medical advice on your symptoms. We strive to prevent heart disease onset, as well as treat and regenerate the heart to help protect millions of people living with heart failure. In 2017, our respiratory medicines reached more than 18 million patients. Healthy Heart Africa is committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) in Africa. cardiovascular and metabolic diseases. 2016. Grants and Donations may be awarded to Healthcare Organisations, Patient Organisations, or … European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108. Heart attack. JAMA. Visit keeptreating.com to learn about the journey of those who want to avoid experiencing a heart attack. The acquisition continues AstraZeneca’s track record of targeted business development with a focus on three main therapy areas. Cavender MA, et al. Of the projects targeting priority diseases, the focus is on COVID-19 (3 projects). At the end of 2015, the company bought Takeda’s res-piratory business for USD 575 mn. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. Eur Heart J. 12. The Microbial Sciences group at AstraZeneca is studying the impact of the microbiome on the host immune response and its potential role in driving chronic disease. Available at:  https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed July 2019. Curr Opin Endocrinol Diabetes Obes. Available from: URL: https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/atherosclerosis. Our country sites can be located in the AZ Network. Programme screening and treatment & Total programme KPIs. Life After a Heart Attack. Remarkably, however, AstraZeneca has the third largest pipeline. Veeva ID: Z4-25396Date of next review: August 2022. Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054. AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. My accountability includes research and development through clinical proof-of-concept for our CVRM pipeline, with a focus on disease modification, regenerative medicine and precision medicine. Working on a strong pipeline means so much more than … Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed. OBI is turning its focus upstream and seeking out earlier changes in the development of CHD, working outside the constraints of traditional biomedical science. This website is intended for people seeking information on AstraZeneca's worldwide business. Association of key risk factors and their combinations on ischemic outcomes in patients with invasively managed myocardial infarction in Sweden. Available from URL: American Heart Association. 2018. Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets). Please refer to your approved national product label (SmPC) for current product information. J Am Coll Cardiol. American Heart Association. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 2014 August ; 21(4): 279–286. AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH). Prevention: Heart attack. Our focus is to transform the lives of the millions of patients living with metabolic diseases. Implementation of a Patient Navigator Program to Reduce 30-day Heart Failure Readmission Rate. The Lancet 2016; 388(10053):1459–544. We have a strong pipeline with more than 33,000 patients participating in Phase I-IV respiratory clinical trials across the world. Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need. SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Measuring blood flow changes in coronary arteries aids application of targeted heart disease therapies to improve patient outcomes, Hope for CKD: Proactive Prevention and Detection Strategies, Making chronic kidney disease a policy priority, Understanding the journey of care for patients with cardiovascular, renal and metabolic disease, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease, https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395, Accepted Available from URL: Di Palo KE, et al. Chronic kidney disease occurs in the context of multiple comorbidities and has been termed as a “disease multiplier.”11 We work to find ways to help patients manage the many complications and provide solutions for better disease management. 2017;70(1):1-25. AstraZeneca has said that they’re aware of 15 events of deep vein thrombosis and 22 events pulmonary embolisms, but that’s in 17 million people who have had at least one shot – … This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. COVID-19 is caused by a virus called coronavirus (SARS CoV 2). Through an agile approach, multidisciplinary team and unique organisational structure, OBI is paving the way for innovative research. A number of advances for AstraZeneca’s drugs have been confirmed. Senior Vice President, CVRM, BioPharmaceuticals Business Unit, SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D. AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas. Our commitment to cardiovascular care began with one of the first oral antihypertensive medications in the 1950s and continued with research leading to new cholesterol-lowering statins in the 1970s. 8. The Global Economic Burden of Non-communicable Diseases. Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 2014, Article ID 937398, 21 pages, 2014. https://doi.org/10.1155/2014/937398. PORTFOLIO AND PIPELINE AstraZeneca has a mid-sized portfolio of rele-vant products, with 41 medicines and one pre-ventive vaccine, and a mid-sized pipeline of 16 doi:10.1097/MED.0000000000000074. An exciting and balanced pipeline underpinned by great science. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020. J Cardiol 2011; 57(1):8–17. 5. National Institute of Diabetes and Digestive and Kidney Diseases. AstraZeneca provides this link as a service to website visitors. Omnichannel marketing is a customer centric approach that allows AstraZeneca to interact with our Healthcare Physicians (HCPs) and Consumers seamlessly across all available channels, delivering a more integrated, informed and connected customer experience – one that drives values for both AstraZeneca and our customers. Learn more about patients living with chronic kidney disease. JernBerg T et al. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Available at. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization. Circulation. I am currently leading the global research and early development group for Cardiovascular, Renal and Metabolism (CVRM) in BioPharmaceuticals R&D at AstraZeneca. The Euro Heart Survey on diabetes and the heart. Heart attack and unstable angina pectoris, are responsible for almost half of all deaths related to cardiovascular disease worldwide. Around one in three patients with acute coronary artery disease (CAD) is estimated to have type-2 diabetes (T2D), and patients with both CAD and diabetes are at almost double the risk for a major adverse cardiovascular event compared to diabetes patients with only risk factors for cardiovascular disease.6,7, In addition, the more risk factors that a patient with a prior heart attack may have – such as diabetes, multivessel disease or chronic kidney disease – the greater the chance of experiencing an event.8, In the US, about 33-46% of the patients with end-stage renal disease have cardiovascular disease (CVD) and about 28-44% have heart failure.9 The presence of CVD is associated with worsening short and long-term survival of end-stage kidney disease patients after a cardiovascular procedure with CVD being a leading cause of death in those patients.10. This collaboration expands compliance with evidence-based guidelines across China. World Heart Day. Atherosclerosis; 2017 [cited 2019 Feb 19]. Our advanced approach to Regulatory means we are leading the field. Developed with the American College of Cardiology (ACC), the Program successfully reduced the readmission rate among primary HF inpatients by using a patient-tailored approach.19, GULLIVE-R (GUideline adherence and risk assessment after acute myocardiaL infarction in real LIfe in Germany – a quality improVEment and awareness Registry of the German Cardiac Society) is a real-world evidence registry following patients from up to 250 hospitals and office-based centres in Germany for 9 to 18 months post-MI. For all Medical Information enquiries, about the AstraZeneca COVID-19 vaccine and to view the Information for UK Vaccine Recipients and Information for Healthcare Professionals please click here.. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Chapter 9: Cardiovascular Disease in Patients With ESRD; 2018. With a strong purpose, an even stronger bond between each of our people and a science-led, patient-first attitude, we’re changing the future of medicine and the … Available from: URL: https://www.usrds.org/2018/view/v2_08.aspx. DGK Pressemitteilung, 25. We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life. AstraZeneca is not responsible for the privacy policy of any third party websites. AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration. Eur Heart J. Just launched in partnership with DGK-Zentrum, the programme provides counselling and lifestyle change support for patients and their treatment, whether risk stratification or routine management.20. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study). The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. (Monday to Friday, 8 AM to 6 PM ET, excluding holidays. 1. To tackle key issues in cardiovascular care and associated complications, AstraZeneca has entered a multi-year partnership with World Heart Federation (WHF), the world’s leading voice for cardiovascular health. Eur Heart J. We are integrated in the drug development teams to influence early on and continue to add value throughout. Important notice for users Circ J. We’re constantly pushing the boundaries of science to deliver life-changing medicines to patients, with a passion for discovery and a pipeline to show for it. 13. Bartnik M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. 10. 2004;25(21):1880–90. Fox KA, et al. The Patient Navigator Program is a transition-care improvement initiative implemented in 35 US hospitals designed to reduce the 30-day all-cause readmission rate following hospitalised heart failure, improving patients’ long-term outcomes,19 which may also lead to reduction of regulatory penalties and optimised financial results for hospitals. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed. I have read this warning and will not be using any of the contained product information for clinical purposes. Our country sites can be located in the AZ Network. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Veeva ID: Z4-25396Date of next review: August 2022. We encourage you to read the privacy policy of every website you visit. Arnold SV et al. 2019. CCC was founded to address the treatment compliance gap, enabling new benchmarks to be set in cardiovascular care. I have read this warning and will not be using any of the contained product information for clinical purposes. Kidney Disease Statistics for the United States: December 2016. We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. Available from: URL: https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. You are about to access AstraZeneca historic archive material. 2. Our enduring goal is to push the boundaries of science to further reduce cardiovascular morbidity and mortality beyond current treatments, and to deliver transformative cardiovascular medicines to the people who need them. COVID-19 Vaccine AstraZeneca is a vaccine used to protect people aged 18 years and older against COVID-19. Geneva, Switzerland: World Economic Forum (cited 2018 Aug 6). dapagliflozin and metformin HCI extended-release. Prog Cardiovasc Dis. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Discover Sanofi's products in the UK. Available from URL: Bhatt DL, et al. (2019). On our Keep Treating portal, we answer questions our patients and healthcare professionals may have and emphasise the importance of their relationship in minimising and managing the risk of a second heart attack. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Available from URL: Healthtalk.org. We are AstraZeneca, one of the world’s most forward-thinking and connected BioPharmaceutical companies. World Health Organization. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. 2019. 11. Presented at: ESC Congress 2018, 2018 Aug 25-29, Munich, Germany. 9. Bjornstad et al. Eur Heart J 2015; 36:1163-1170. Jernberg T, et al. LONDON, UK I March 25, 2020 I AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small …